Mammographic screening induces a 25 percent reduction in breath cancer mortality according to a meta-analysis.
But there is still a controversy about the value of the ratio Benefit/harm of breath cancer screening among public health searchers. A norwegian public health searcher states that it is possible that 36% of invasive breath cancer of organised mammography screening programs could be in fact overdiagnosed.
Further research should be to implement on that matter with regard of the human and economic cost of over-diagnosis.
Indeed there is only two possibilities when a cancer is screened by organised program: either it is advanced diagnosis or it is over-diagnosis. In the first case the cancer would have been clinically diagnosed later after the lead time interval. In the second case the cancer would have never been clinically diagnosed during the remaining life time of the women.